66 results about "Medullary Hematopoiesis" patented technology

In part, the present disclosure relates methods for treating, preventing, or reducing the progression rate and/or severity of myelofibrosis or one or more complications of myelofibrosis (extramedullary hematopoiesis, splenomegaly, anemia, and fibrosis). In certain aspects, the disclosure provides ActRIIB antagonists for use in treating, preventing, or reducing the progression rate and/or severity of one or more complications associated with Janus kinase inhibitor therapy in a patient (e.g., anemia).

The invention relates to a traditional Chinese medicine composition for treating tumors, the traditional Chinese medicine composition comprises ganoderma lucidum, ganoderma sinensis, coriolus versicolor, antrodia camphorate, agaricus blazei, grifola frondosa, ginseng and ganoderma lucidum spore oil; or the traditional Chinese medicine composition is prepared by taking ganoderma lucidum, ganoderma sinensis, coriolus versicolor, antrodia camphorate, agaricus blazei, grifola frondosa, ginseng and ganoderma lucidum as raw materials and further comprises ganoderma lucidum extract, ganoderma sinensis extract, coriolus versicolor extract, antrodia camphorate extract, agaricus blazei extract, grifola frondosa extract, ginseng extract and the ganoderma lucidum spore oil. The traditional Chinese medicine composition for treating the tumors can assist to suppress the growth of the tumors, resist the injuries of chemo-radiation therapy, promote the bone marrow hematopoiesis and improve the immunity. The invention further relates to a production method of the traditional Chinese medicine composition for treating the tumors.

The invention discloses a method for making a blood fat reducing and bone strengthening biscuit. The preparation raw materials comprise pig bone, flour, shortening, cherokee rose fruit, acanthopanax root, platycodon grandiflorum, balsam pear leaf, curcuma, filbert, lalang grass rhizome, buckeye and fennel. The processing method for the biscuit has a simple process, is convenient to operate and is suitable for industrial continuous production. The added pig bone is warm in nature and has the effects of tonifying spleen qi, moistening intestines and stomach, promoting secretion of saliva or body fluid, fatting the body, smoothing the skin, invigorating spleen-stomach, replenishing qi, nourishing blood and strengthening the bone; the substances such as ossein necessary for the human body can be timely supplemented if a child drinks bone soup frequently, so that the medullary hematopoiesis function is enhanced, and the growth and the development of the bone are promoted; the aging can be delayed if an adult drinks the bone soup; due to the Chinese medicinal ingredients such as the cherokee rose fruit, the acanthopanax root, the filbert and the lalang grass rhizome in the raw materials, the product has the effects of reducing the blood fat and preventing and controlling hyperlipidemia.

The invention provides a pharmaceutical composition for treating thrombocytopenia, which comprises gen-seng, epimeddium, radix astragali, angelica sinensis, radix rehmanniae preparata, spatholobus stems, hairyvein agrimony, and tangerine peel. The pharmaceutical composition of the invention can be prepared into clinically-acceptable dosage forms by adding routine auxiliary materials according to routine technology. The pharmaceutical composition of the invention has significant effect on treating thrombocytopenia and leucopenia, promoting proliferation of bone marrow hematopoietic stem cells, repairing damage and injury of bone marrow hematopoietic tissue caused by radiation, preventing marrow inhibition caused by radiotherapy and chemotherapy, or improving symptoms and increasing life quality of tumor patients, and has no side effect.

The invention provides a novel method to prepare a purified human stromal derived factor-1 Alpha(hSDF-1 Alpha), which can greatly simplify purification process, save cost, and improve purity and yield of the produce. The human stromal derived factor-1 Alpha prepared through the method is capable of activating the chemotaxis of T cells and mobilizing medullary hematopoiesis. The invention also provides a new human stromal derived factor-1 Alpha, the pharmaceutical composite and the application thereof.

The invention relates to a health product preparation which improves the proliferation ability of bone marrow hematopoietic stem cells to achieve the purposes of anti-aging and anti-anaemia and according to weights, the health product preparation is prepared with the following medicinal material components: 60g to 90g of donkey hide gelatin, 60g to 90g of sophora flowers, 120g to 250g of astragalus, 120g to 250g of rhizoma pollgonati, 90g to 150g of prepared radix rehmanniae, 20g to 55g of glycyrrhiza, 15g to 30g of lactose, 25g to 60g of pre-gelatinized starch and 15g to 30g of maltodextrin. The health product preparation plays the roles of strengthening human immunity, antioxidation and anti-aging, anti-anaemia and improving growth and development and has an auxiliary protection function for chemical liver injury. After being taken by various populations according to requirements, the preparation achieves the purposes of building up bodies, resisting diseases, delaying aging and improving growth and development by strengthening immunity and antioxidation function and has an auxiliary protection function for chemical liver injury, and the preparation is also beneficial to body trouble or various diseases.

The invention discloses a blood-tonifying beautifying anti-aging red bean porridge and a making method thereof. The porridge consists of the following materials: red beans, polished round-grained rice, black beans, jujube, crystal sugar, a grape seed powder, a cucumber seed powder, coix seed, broccoli, carrot, raspberry, a pseudo-ginseng powder, Juniper berry, buckthorn fruit, dodder, garden burnet, Samara chrysanthemum, Ligusticum wallichii, medlar, folium Apocyni Veneti, peanut coat, roses and a proper amount of water. The buckthorn fruit in the formula provided by the invention has effects of caring skin, resisting aging, tonifying the spleen and nourishing the stomach; the Juniper berry and Samara chrysanthemum can sterilize, detoxicate, clear heat and cause diuresis; the peanut coat promotes hematopoietic function of bone marrow and plays a role of nourishing and supplementing blood; at the same time, the added cucumber seed powder can relax bowel; the grape seed powder has effects of delaying aging, whitening and beautifying; and the pseudo-ginseng can invigorate the circulation of blood, and play the roles of enriching the blood, nourishing skin and resisting aging.

The invention discloses a Chinese medicinal composition for raising leucocytes, which is mainly prepared from the following raw material medicaments in part by weight: 6 to 60 parts of astragalus, 6 to 60 parts of Siberian solomonseal rhizome, 6 to 60 parts of Mongolian snakegourd root and 3 to 30 parts of epimedium herb. The invention also discloses a method for preparing the Chinese medicinal composition and application thereof in preparation of a medicament for treating leucopenia, improving immune function of an organism, promoting proliferation of marrow hematopoietic stem/progenitor cells, protecting hemopoietic microenvironment, repairing the damage and harm to marrow hematopoietic tissues by radioactive rays, preventing and controlling marrow suppression of chemoradiotherapy, promoting colony formation of granulocytes and monocytes, improving Chinese medicinal symptoms and living quality of patients with cancer, or promoting the recovery of patients with Qi-Yin deficiency.

The invention discloses applications of a fullerene structure in preparation of drugs used for treating leukemia. The fullerene structure is taken as an active ingredient, and comprises at least one ingredient selected from an oil soluble fullerene, an oil soluble metal embedded fullerene, a composition of the oil soluble fullerene and the oil soluble metal embedded fullerene, a water soluble fullerene, a water soluble metal embedded fullerene, a composition of the water soluble fullerene and the water soluble metal embedded fullerene, and a pharmaceutical ester or a pharmaceutical salt of theabove six ingredients. The active ingredient is capable of accumulating in bone marrow at a high efficiency; effects are achieved quickly; excellent biocompatibility is achieved; the fullerene structure can be used for preventing and treating leukemia before leukemia model maturation; after leukemia onset, the active ingredient possesses bone marrow part targeted enrichment characteristics, and can be used for rapid prevention, treatment, and repairing of bone marrow haematopoietic function damages by leukemia and other organic damages.

The invention provides application of a SphK2 inhibiting agent ABC294640 in improving hematopoietic stem cell functions and treating hematopoietic dysfunction. The ABC294640 can be used for treating essential hematopoietic dysfunction, or radiation and chemical drug irritated hematopoietic dysfunction, and is capable of improving hematopoietic stem cell functions to improve the recovery rate and the survive rate of hematopoietic function of a patient after chemotherapy is carried out for a plurality of times. According to the drug, a new drug source is provided to treat essential or induced hematopoietic dysfunction diseases.

The invention provides a preparation method for promoting generation of human bone marrow hematopoietic stem cells, and relates to a manufacture method of stem cells preparation. The method successively comprises the following steps of: a, collecting bovine placenta and fetal bovine marrow; b, cleaning, and sterilizing; c, separating protein, fat and active materials through a freezing centrifugal machine in an ultrafiltration method, so that the sediment is obtained; d, adding pepsase; e, adding water, and extracting to obtain fetal bovine marrow active polypeptide; f, getting the fetal bovine marrow active polypeptide, banana seedcase element and echinacea polysaccharide to be uniformly mixed to obtain marrow polysaccharide; g, getting the marrow polysaccharide, adding the water, and adding strontium, zinc, selenium, iodine, metasilicic acid, calcium, magnesium, potassium, sodium, iron, copper, lithium and nickel, and adjusting a pH value to be alkalescent, and then compounding to obtain a biological activity oral liquid preparation suitable for a human body. The preparation method has the beneficial effect that the human medullary hematopoiesis can be promoted to produce the hematopoietic stem cells; and an unique effect of treating various diseases can be achieved; and the preparation method is safe, efficient and has low cost, and prevention, health care and treatment effects can be achieved.

The invention discloses a sanguisorba officinalis aglycone lipidosome, which is prepared from the following raw and auxiliary materials in proportion by weight: 1 part of sanguisorba officinalis aglycone and 2 to 40 parts of carrier materials, wherein the carrier materials are prepared from hydrogenated soybean phospholipids, distearoyl phosphoethanolamine-polyethyleneglycol 2000 and cholesterin according to a weight ratio of 5:(1 to 4):(1 to 2). The invention also provides a preparation method and a purpose of the lipidosome. The lipidosome has the advantages that the number of peripheral blood leucocytes, neutrophilic granulocytes, red cells, blood platelets, hemoglobin and bone marrow hematopoietic stem cells can be obviously increased; and the obvious effects of treating and/or preventing bone marrow suppression are achieved.

The invention discloses anti-cancer and hemostatic Chinese patent drug which comprises the following components by weight: 150 to 200 parts of salsola-like inula flower and herb, 100 parts of white atractylodes rhizome, 100 parts of zedoary, 100 parts of Chinese angelica root, 100 parts of psoralea fruit, 100 parts of pinellia tuber, 100 parts of fritillary bulb, 100 parts of asarum sagittarioides, 60 parts of ginseng, 40 parts of American ginseng, 50 parts of astragalus root, 50 parts of white peony root, 30 parts of rhizome of Sichuan lovage, 50 parts of ass-hide glue, 50 parts of bark of chinese cassia tree, 40 parts of Mabuzi, 7 parts of Banmo, 3 parts of arenobufagin and 40 parts of borneol. The Chinese patent drug has the effects that the curative effect is quick, the Chinese patent drug can effectively restrain complications, is broad-spectrum and anti-cancer, safe, reliable, short in course of treatment, and overcomes the problem of the multidrug resistance of cancer cells, patients can not suffer a relapse after being healed, and the Chinese patent drug has the function of improving the medullary hematopoiesis.

The invention disclosesan application of an IL-12p40 (-/-) IL-2R alpha (-/-) mouse model and belongs to the technical field of medical biology. Compared with IL-12p40 (-/-) IL-2R alpha (+/-) mouse as a control mouse, an IL-12p40(-/-)IL-2R alpha(-/-) mouse is abnormal in a hematopoietic system in the following aspects: quantities of red blood cells and leukocytes in peripheral blood are reduced; CD4<+>T cells and CD8<+>T cells in bone marrow are abundantly infiltrated, proportion and quantity of LSK cells (Lin<->c-Kit<+>Sca-1<+> cells)are increased, hematopoietic capacity of the marrow declines, and reticular fibers appear in the marrow; splenomegaly occurs, and the spleen and the liver show extramedullary hematopoiesis. Therefore, the IL-12p40(-/-)IL-2R alpha(-/-) mouse can be takenas an animal model to be used for screening autoimmune myelofibrosis treatment drugs.

The invention discloses the novel purposes of a ferulic acid and a preparation thereof in curing medullary hematopoiesis dysfunction caused by low-dose radiation; the action mechanism increases visible components in peripheral blood by promoting medullary hematopoiesis, plays a significant role in curing the medullary dysfunction caused by low-dose radiation, and can provide clinical medicine with definite efficacy and high bioavailability for clinically curing low-dose radiation.

The invention provides an Endomucin antibody medicament for prompting bone marrow regeneration. Endomucin has a negative regulation effect on the proliferation and differentiation of hematopoietic cells, namely, the Endomucin has an inhibiting effect on the recovery and regeneration of bone marrow, while an Endomucin antibody can weaken the inhibiting effect and promote the recovery of a bone marrow hematopoietic function. When a medicinal preparation prepared from an Endomucin monoclonal antibody prepared via a myeloma cell fusing technology is adopted for treating a mouse undergoing 5-Fu (5-fluorouracil) chemotherapy, the recovery and regeneration of bone marrow cells can be promoted, the survival rate of the mouse undergoing the chemotherapy can be increased remarkably, and a bone marrow regeneration function is promoted remarkably. The Endomucin has great potential clinical application and research values on the aspect of regulation of the bone marrow hematopoietic function.

The invention discloses a single cell transcriptome map of human bone marrow hematopoietic stem/progenitor cells and a construction method. The method comprises the following steps: (1) sorting human bone marrow hematopoietic stem/progenitor cells; (2) constructing a single cell transcriptome library of the human bone marrow hematopoietic stem/progenitor cells; (3) sequencing the single cell transcriptome library; (4) analyzing the sequenced data, and constructing a single cell transcriptome map of the human bone marrow hematopoietic stem/progenitor cells; through deep single cell transcriptome sequencing, the single cell transcriptome map of the human bone marrow hematopoietic stem/progenitor cells is constructed to systematically research the characteristics of the human hematopoietic stem/progenitor cells, more information is obtained, and a theoretical basis can be provided for exploring physiological and pathological hematopoiesis of the human bone marrow hematopoietic stem/progenitor cells.

The invention relates to the field of biological medicines, in particular to application of a compound RADNOVA in preparation of anti-radiation medicines. The application has the beneficial effects that the new application of the compound RADNOVA in radiation resistance is discovered and proved for the first time, and the compound RADNOVA has an outstanding effect in the aspects of intestinal tract tissue damage and bone marrow hematopoietic system damage caused by radiation resistance.

The invention discloses application of glycyrrhetinic acid to prevention and treatment of stem cell senescence. The glycyrrhetinic acid can regulate and control senescence of bone marrow hematopoieticstem cells from a gene level and improve functions of the senescent bone marrow stem cells. After the glycyrrhetinic acid is added into the senescent cells for culturing, galactosidase staining positive cells are reduced. In a mouse senescence model, spleen extramedullary hematopoiesis of senescent mice after the glycyrrhetinic acid is applied is relieved, and myeloid differentiation tendency ofbone marrow hematopoiesis is rescued. The glycyrrhetinic acid can regulate the senescent stem cells and improve inflammatory senescence through programmed control of the gene level, plays a role in preventing and treating senescence of the stem cells, and provides a new idea for clinical application of hematopoietic stem cell transplantation. The glycyrrhetinic acid can directly target an inflammatory factor IL-6, patients with novel coronavirus (2019-nCoV) outbreaking in 2019 accompany high-level IL-6, and effective drugs, pneumonia No.1 and Lianhua Qingwen Granule, at present both contain liquorice components, so that the glycyrrhetinic acid is expected to provide a reference for novel coronavirus treatment.

The invention belongs to the technical field of bio-medicine, particularly relates to a new application of an olive leaf crude extract and a tumor therapeutic drug combined kit thereof, and discloses an application of the olive leaf crude extract in preparation of a drug or a health-caring product which is used for treating or preventing inhibition of immunologic function or inhibition of medullary hematopoiesis caused by drugs in radiotherapy and/or chemotherapy. The olive leaf crude extract can significantly increase the number of peripheral blood leucocytes and bone marrow cells, can effectively reduce side effects of the inhibition of the immunologic function or the inhibition of the medullary hematopoiesis caused by the drugs in radiotherapy and/or chemotherapy, and may provide a new selection in clinical therapy of tumors in future.

The present invention provides peptide drug series that can promote the proliferation of marrow hematopoietic cells. The main amino acid sequence of the short peptide fragments, analogs, derivants and variants of the short peptide of the peptide drug series is larger than or equal to 70 percent equal to and larger than or equal to 90 percent similar to the main amino acid sequence of the short peptide. The short peptide, nucleotides, short peptide fragments, short peptide analogs, short peptide derivants and short peptide variants are used for the preparation of drugs for treating manifold marrow hematopoietic cell defection diseases, congenital anaemia, aplastic anemia and various hemorrhagic anemia diseases and can be applied to the bone marrow transplantation of leukemia patients, etc., that is, the peptide drug of the present invention can treat pancytopenia caused by hemopoietic stem cell defects.